Paul Moorehead/LinkedIn
Aug 6, 2025, 10:47
Conquering Factor VIII Inhibitors: New Insights Into the ‘Devil’ of Hemophilia A Treatment Resistance
Flora Peyvandi posted on X:
”Exorcizing the devil of factor VIII inhibitors”
“For the Devil is a gentleman, and doesn’t keep his word” – G.K. Chesterton
In this issue of Blood Advances, Butera et al shed some light on the mystery of factor VIII (FVIII) inhibitors, the most diabolical complication of FVIII replacement therapy in patients with hemophilia A. Their work examined the impact of disulfide bonds on the antigenicity of the FVIII molecule, with possible implications for the understanding of immune responses to exogenous FVIII and for drug design.
Read the full article here.
Auothor: Paul C. Moorehead
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 19:35Luise Erpenbeck: When Immune Cells Speak the Language of Neurons
-
Jul 5, 2026, 19:14Mubariz Ahsan: Bringing Stroke Research to a Wider Audience
-
Jul 5, 2026, 18:58Linda Hayes Bennett: Redefining Ferroptosis in Aging and Neurodegenerative Conditions
-
Jul 5, 2026, 18:20LV Aneurysm, Thrombus, and Embolism: A Silent Post-MI Threat – Abdallah Othman
-
Jul 5, 2026, 17:58Andaleb Kholmukhamedov: What’s the Most Unusual “False Positive” Trigger You’ve Seen Elevate a D-Dimer?
-
Jul 5, 2026, 17:47Michiel Coppens: Supporting Better Hemophilia Care in Suriname
-
Jul 5, 2026, 17:31Arrigo Francesco Giuseppe Cicero: Redefining the Role of Urate-Lowering Therapy in Cardiovascular Disease
-
Jul 5, 2026, 17:20Ahmad Gharehbaghian: Iranian Blood Transfusion Organization Engages Government Leaders on Blood Service Investment
-
Jul 5, 2026, 17:03Paolo Zamboni։ New Findings Highlight PLXND1 as a Critical Mechanosensor in Primary Lymphedema